Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in low or intermediate-1 risk MDS
NCT00486720Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Primary completion
- Jul 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 2, randomised, open-label trial of vorinostat in myelodysplastic syndrome (MDS) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Responders and Number of Non-responders Defined by International Working Group Response Criteria at 2 years and Safety and Tolerability as Assessed by the Number of Participants With Adverse Events. Started Jun 2007; status: terminated.
02
Drugs
vorinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00486720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00486720.